Business
Endonovo Therapeutics Announces Enrollment of First Patient in Clinical Study at the University of New Mexico for Treating Traumatic Brain Injury Using Its Electroceutical™ Therapy
Endonovo Therapeutics Announces Enrollment of First Patient in Clinical Study at the University of New Mexico for Treating Traumatic Brain Injury Using Its Electroceutical™ Therapy.
About this update from Endonovo Therapeutics, Inc.
[{"type":"text","content":"\nLOS ANGELES, CA, June 14, 2018 (GLOBE NEWSWIRE) -- Endonovo Therapeutics, Inc. (OTCQB: ENDV) (\"Endonovo\" or the \"Company\"), a commercial-stage developer of Electroceutical™ Therapies, today announced that the first patient has been enrolled in a clinical study at the University of New Mexico Health Sciences Center that will evaluate the effects of Pulsed Electromagnetic Fields (PEMF) on reducing brain injury, blood-brain-barrier and inflammation biomarkers in the cerebrospinal fluid and blood in patients with brain injury who are or have been fitted to an external ventricular drain. Funding for the study has been secured via the Company's senior secured Series C Preferred Stock financing.\n \"The initiation of this study represents a significant milestone for Endonovo,\" said Endonovo CEO, Alan Collier. \"We believe our technology, whose proven mechanism of action is the suppression of inflammation, has the potential to change the treatment of central nervous system disorders where neuroinflammation propagates injury such as ischemic stroke, Alzheimer's disease and Multiple Sclerosis.\" \"After completing two PEMF safety studies on volunteers and patients with brain injury currently submitted for publication, we have consented and studied our first severe traumatic brain injury patient for the PEMF study and collected brain fluid and serum samples for four days post-injury,\" said Edwin Nemoto, PhD, University of New Mexico Health Sciences Center, School of Medicine, Department of Neurosurgery. About the Study The randomized, double-blind, placebo-controlled, clinical study is an extension of a safety trial that will be open to all patients who have or are fitted with an external ventricular drain (EVD) to remove excess cerebrospinal fluid (CSF). The study will enroll 48 patients with brain injury and will assess the effects of PEMF on suppressing the release of brain injury, blood brain barrier and inflammatory biomarkers in the cerebrospinal fluid and blood for up to one week after severe TBI with neurologic outcome follow up at one and three months. CSF will be collected at baseline and then every 8 hours until EVD is removed. CSF samples will be analyzed for biomarkers, such as IL-1β, IL-10 and S100 and other outcomes such as ICP, tissue oxygenation, blood flow, vital signs, and variables specific to individ...